Artemis - Ziltivekimab Started During Hospitalization For Type 1 Myocardial Infarction
Posted Date: May 15, 2025
- Investigator: Imran Arif
- Specialties:
- Type of Study: Drug
This study investigates using ziltivekimab, a novel treatment, in patients hospitalized for a myocardial infarction to determine its effectiveness in reducing future cardiovascular events. The trial is a 1:1 randomized, Phase 3 study comparing ziltivekimab to a placebo over approximately 2 years. Primary outcomes include the time to major adverse cardiovascular events, while secondary outcomes encompass a range of cardiovascular health metrics and hospitalizations.
Criteria:
Stemi Or Nstemi With Defined Ecg And Biomarker Criteria
Keywords:
Reducing Inflammation After Acute Mi
For More Information:
Elias Shamieh
513-558-3016
shamiees@ucmail.uc.edu